Editorial
Glioblastoma radiosensitization by pimozide
Translational Cancer Research
2016;
5
(Suppl 6)
:S1029-S1032
.
(30 November 2016)
MLK4 activates the NF-κB network to drive mesenchymal transition in glioblastoma
Translational Cancer Research
2016;
5
(Suppl 6)
:S1033-S1038
.
(30 November 2016)
Mesenchymal stromal cells and interferon α (IFNα) in cancer immunotherapy
Translational Cancer Research
2016;
5
(Suppl 6)
:S1039-S1043
.
(30 November 2016)
Rethinking clinical trial design: maximizing the results from each clinical trial participant
Translational Cancer Research
2016;
5
(Suppl 6)
:S1044-S1046
.
(30 November 2016)
INTEGRATE phase II trial: regorafenib vs. placebo in pretreated metastatic gastric cancer patients—is there anything new?
Translational Cancer Research
2016;
5
(Suppl 6)
:S1047-S1050
.
(30 November 2016)
Hedgehog signaling in colorectal cancer: a spiny issue gets smoothened
Translational Cancer Research
2016;
5
(Suppl 6)
:S1051-S1054
.
(30 November 2016)
An ace in the hole for hepatocellular carcinoma: yttrium-90 radioembolization
Translational Cancer Research
2016;
5
(Suppl 6)
:S1055-S1056
.
(30 November 2016)
New insights into the mechanisms of EZH2’s promotion of oncogenesis
Translational Cancer Research
2016;
5
(Suppl 6)
:S1057-S1060
.
(30 November 2016)
Is there still an open window in metastatic castration resistant prostate cancer immunotherapy horizon?
Translational Cancer Research
2016;
5
(Suppl 6)
:S1061-S1065
.
(30 November 2016)
Risk of contralateral breast cancer amongst BRCA1/2 mutation carriers
Translational Cancer Research
2016;
5
(Suppl 6)
:S1066-S1069
.
(30 November 2016)
Determination of the optimal screen interval in low-dose CT lung cancer screening: are we there yet?
Translational Cancer Research
2016;
5
(Suppl 6)
:S1070-S1072
.
(30 November 2016)
Prostaglandin E2 plays a major role in glioma resistance and progression
Translational Cancer Research
2016;
5
(Suppl 6)
:S1073-S1077
.
(30 November 2016)
Information-dense analysis for information-dense understanding
Translational Cancer Research
2016;
5
(Suppl 6)
:S1078-S1081
.
(30 November 2016)
Thriving where others have faltered—a critical appraisal of the role of patient factors versus treatment effect in JCOG0605 trial in relapsed small cell lung cancer
Translational Cancer Research
2016;
5
(Suppl 6)
:S1082-S1084
.
(30 November 2016)
The use of malaria glycosaminoglycan to block cancers—lessons from the human placenta
Translational Cancer Research
2016;
5
(Suppl 6)
:S1085-S1087
.
(30 November 2016)
A genomic analysis of large cell neuroendocrine carcinoma versus small cell lung cancer: which is which?
Translational Cancer Research
2016;
5
(Suppl 6)
:S1088-S1092
.
(30 November 2016)
Pancreatic cancer cell invasion: mesenchymal switch or just hitchhiking?
Translational Cancer Research
2016;
5
(Suppl 6)
:S1093-S1097
.
(30 November 2016)
Subventricular zone microenvironment protects glioblastoma cells from radiotherapy cytotoxicity: role of the chemokine CXCL12
Translational Cancer Research
2016;
5
(Suppl 6)
:S1098-S1101
.
(30 November 2016)
Sleeve lobectomy or pneumonectomy for non-small cell lung cancer? Searching for an optimal balance between oncological, surgical and functional results
Translational Cancer Research
2016;
5
(Suppl 6)
:S1102-S1106
.
(30 November 2016)
The potential role of curcumin in prostate cancer: the importance of optimizing pharmacokinetics in clinical studies
Translational Cancer Research
2016;
5
(Suppl 6)
:S1107-S1110
.
(30 November 2016)
The unexpected high risk of occurrence or recurrence of hepatocellular carcinoma after successful antiviral therapy with interferon-free direct-acting antivirals
Translational Cancer Research
2016;
5
(Suppl 6)
:S1111-S1115
.
(30 November 2016)
Interfering with Helios-induced regulatory T cell stability as a strategy for cancer immunotherapy
Translational Cancer Research
2016;
5
(Suppl 6)
:S1116-S1118
.
(30 November 2016)
Role of adaptive randomization in developing novel therapies for patients with breast cancer
Translational Cancer Research
2016;
5
(Suppl 6)
:S1119-S1122
.
(30 November 2016)
Resistance mechanisms to PD-1 inhibition in melanoma
Translational Cancer Research
2016;
5
(Suppl 6)
:S1123-S1125
.
(30 November 2016)
Advances in molecular genetics of early-stage urothelial carcinoma
Translational Cancer Research
2016;
5
(Suppl 6)
:S1126-S1130
.
(30 November 2016)
Moving from immune phenotyping of colorectal cancer to mechanistic insights on aspirin use
Translational Cancer Research
2016;
5
(Suppl 6)
:S1131-S1134
.
(30 November 2016)
Interplay between MMP-8 and TGF-β1 and its role in regulation of epithelial to mesenchymal transition in hepatocellular carcinoma
Translational Cancer Research
2016;
5
(Suppl 6)
:S1135-S1138
.
(30 November 2016)
Commentary
Is microRNA expression profile in prostate cancer dependent on clinicopathologic stage or cell subtype?
Translational Cancer Research
2016;
5
(Suppl 6)
:S1139-S1141
.
(30 November 2016)
Cisplatin, etoposide, and irinotecan for relapsed small-cell lung cancer
Translational Cancer Research
2016;
5
(Suppl 6)
:S1142-S1144
.
(30 November 2016)
Turning the concept of synthetic lethality on its head
Translational Cancer Research
2016;
5
(Suppl 6)
:S1145-S1148
.
(30 November 2016)
Dealing with complexity: prognostic implications of karyotype and mutations in chronic lymphocytic leukemia
Translational Cancer Research
2016;
5
(Suppl 6)
:S1149-S1152
.
(30 November 2016)
Thoracoscopic surgery for lung cancer without interruption of anti-platelet agents: is it really safe?
Translational Cancer Research
2016;
5
(Suppl 6)
:S1153-S1156
.
(30 November 2016)
Is the ColDx assay a valid prognostic marker for stage II colon cancer?
Translational Cancer Research
2016;
5
(Suppl 6)
:S1157-S1159
.
(30 November 2016)
Eribulin in the soft tissue sarcoma therapeutic landscape: little is good, then more is better
Translational Cancer Research
2016;
5
(Suppl 6)
:S1160-S1162
.
(30 November 2016)
Identifying ADP-ribosylation targets by chemical genetics
Translational Cancer Research
2016;
5
(Suppl 6)
:S1163-S1166
.
(30 November 2016)
Implications of the lymph nodal ratio in resected N1 non-small cell lung cancer
Translational Cancer Research
2016;
5
(Suppl 6)
:S1167-S1169
.
(30 November 2016)
Predicting disease recurrence in stage II colon cancer: expression signatures and other biomarkers
Translational Cancer Research
2016;
5
(Suppl 6)
:S1170-S1172
.
(30 November 2016)
Clinical data and role of ceritinib a second-generation ALK tyrosine kinase inhibitor for the treatment of ALK positive non-small cell lung cancer
Translational Cancer Research
2016;
5
(Suppl 6)
:S1173-S1176
.
(30 November 2016)
Unraveling epigenetic regulation of epithelial mesenchymal transition
Translational Cancer Research
2016;
5
(Suppl 6)
:S1177-S1180
.
(30 November 2016)
Biomarker guided treatment of advanced non-small cell lung cancer: does feasibility translate to improvements in patient care?
Translational Cancer Research
2016;
5
(Suppl 6)
:S1181-S1184
.
(30 November 2016)
G-protein coupled receptor PAR1 is overexpressed in glioma progenitor cells
Translational Cancer Research
2016;
5
(Suppl 6)
:S1185-S1188
.
(30 November 2016)
Xist at the edge: silencing at the nuclear periphery extends to X inactivation
Translational Cancer Research
2016;
5
(Suppl 6)
:S1189-S1191
.
(30 November 2016)
Genetic and epigenetic alterations in urothelial carcinoma
Translational Cancer Research
2016;
5
(Suppl 6)
:S1192-S1195
.
(30 November 2016)
Loss of LARP4B, an early event in the tumorigenesis of brain cancer?
Translational Cancer Research
2016;
5
(Suppl 6)
:S1196-S1199
.
(30 November 2016)
A vicious cycle of metabolic interaction between leukemia stem cells and adipose tissues: implications in cachexia and drug resistance
Translational Cancer Research
2016;
5
(Suppl 6)
:S1200-S1203
.
(30 November 2016)
miRNA profile as a predictor of response to chemoradiation therapy for esophageal squamous cell carcinoma
Translational Cancer Research
2016;
5
(Suppl 6)
:S1204-S1207
.
(30 November 2016)
JAK3-mediated phosphorylation of EZH2: a novel mechanism of non-canonical EZH2 activation and oncogenic function
Translational Cancer Research
2016;
5
(Suppl 6)
:S1208-S1211
.
(30 November 2016)
AKT inhibition: a bad AKT inhibitor in liver injury and tumor development?
Translational Cancer Research
2016;
5
(Suppl 6)
:S1212-S1213
.
(30 November 2016)
Perspective
Is there a role for epidermal growth factor receptor inhibition in the treatment of advanced esophagogastric tumours?
Translational Cancer Research
2016;
5
(Suppl 6)
:S1214-S1221
.
(30 November 2016)
Molecular cross-talk between the liver and white adipose tissue links excessive noURIshment to hepatocellular carcinoma
Translational Cancer Research
2016;
5
(Suppl 6)
:S1222-S1226
.
(30 November 2016)
Lung cancer screening: screening frequency and lung cancer risk
Translational Cancer Research
2016;
5
(Suppl 6)
:S1227-S1232
.
(30 November 2016)
Adding to the targeted therapy toolbox: BRAF and MEK inhibition in the treatment of BRAF V600E metastatic non-small cell lung cancer
Translational Cancer Research
2016;
5
(Suppl 6)
:S1233-S1240
.
(30 November 2016)
Contemporary management of renal angiomyolipomas
Translational Cancer Research
2016;
5
(Suppl 6)
:S1241-S1247
.
(30 November 2016)
MET-inhibitors meet MET mutations in lung cancer
Translational Cancer Research
2016;
5
(Suppl 6)
:S1248-S1254
.
(30 November 2016)
Combination chemotherapy for relapsed small-cell lung cancer—perspective on mechanisms of chemoresistance
Translational Cancer Research
2016;
5
(Suppl 6)
:S1255-S1261
.
(30 November 2016)
MicroRNAs as novel elements in personalized radiotherapy
Translational Cancer Research
2016;
5
(Suppl 6)
:S1262-S1269
.
(30 November 2016)
Perspective on targeting salt-inducible kinase 2 (SIK2) in ovarian cancer metastasis
Translational Cancer Research
2016;
5
(Suppl 6)
:S1270-S1273
.
(30 November 2016)
Protease-activated receptor 1 (PAR1): a promising target for the treatment of glioblastoma?
Translational Cancer Research
2016;
5
(Suppl 6)
:S1274-S1280
.
(30 November 2016)
Neoadjuvant chemotherapy versus chemoradiation for esophageal cancer: no survival difference does not mean no differences
Translational Cancer Research
2016;
5
(Suppl 6)
:S1281-S1283
.
(30 November 2016)
In vivo cancer metabolism is defined by the nutrient microenvironment
Translational Cancer Research
2016;
5
(Suppl 6)
:S1284-S1287
.
(30 November 2016)
The p53 orbit in chronic myeloid leukemia: time to move to patient care
Translational Cancer Research
2016;
5
(Suppl 6)
:S1288-S1291
.
(30 November 2016)
Correspondence
IL2 based immunotherapies: towards a personalized and curative antitumor response
Translational Cancer Research
2016;
5
(Suppl 6)
:S1292-S1294
.
(30 November 2016)
Immunotherapy of pancreatic cancer—weal and woe
Translational Cancer Research
2016;
5
(Suppl 6)
:S1295-S1296
.
(30 November 2016)
The regulation of cancer cell glutamine metabolism
Translational Cancer Research
2016;
5
(Suppl 6)
:S1297-S1298
.
(30 November 2016)
Trans-arterial embolization for hepatocellular carcinoma: doxorubicin is not necessary
Translational Cancer Research
2016;
5
(Suppl 6)
:S1299-S1301
.
(30 November 2016)
Cancer-like mutations in non-cancer tissue: towards a better understanding of multistep carcinogenesis
Translational Cancer Research
2016;
5
(Suppl 6)
:S1302-S1304
.
(30 November 2016)
Targeted attack: mechanisms by which ovarian cancers suppress the immune system
Translational Cancer Research
2016;
5
(Suppl 6)
:S1305-S1306
.
(30 November 2016)
Disclosure:
This supplement was published without any sponsorship or funding.
